Home → E-shop → Nucleotides → Nelarabine triphosphate – CAS 847649-96-1

Nelarabine triphosphate – CAS 847649-96-1

Nelarabine triphosphate – CAS 847649-96-1 is synthesised by Sigut Labs (Prague, Czech Republic).

Purity (LC-MS)

97%+

Package contents

Nelarabine triphosphate Et₃NH⁺salt

This compound is for research use only. We do not sell to patients.

Amount

1 mg		€ 2500	Stock
Do you want custom amount?				Custom amount

Amount

1 mg

€ 2500

Stock

Do you want custom amount?

Custom amount

Characterisation

CAS: 847649-96-1

IUPAC name: ((2R,3S,4S,5R)-5-(2-amino-6-methoxy-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl tetrahydrogen triphosphate

Other names: Arranon triphosphate

Molecular weight: 537.21 g/mol

Molecular formula: C₁₁H₁₈N₅O₁₄P₃

InChI: InChI=1S/C11H18N5O14P3/c1-26-9-5-8(14-11(12)15-9)16(3-13-5)10-7(18)6(17)4(28-10)2-27-32(22,23)30-33(24,25)29-31(19,20)21/h3-4,6-7,10,17-18H,2H2,1H3,(H,22,23)(H,24,25)(H2,12,14,15)(H2,19,20,21)/t4-,6-,7+,10-/m1/s1

Description

Nelarabine triphosphate is an active form of a drug Nelarabine (brand names Arranon (US) and Atriance (EU)). Nelarabine is a chemotherapy medication used for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). Nelarabine is a prodrug of arabinosylguanine nucleotide triphosphate (araGTP), a type of purine nucleoside analog, which causes inhibition of DNA synthesis and cytotoxicity. Pre-clinical studies suggest that T-cells are particularly sensitive to nelarabine.

Chemicals are distributed worldwide

Buy Nelarabine triphosphate now, and get your order in 48 hours

Shipping through DHL in 48 hours
Sensitive compounds are shipped on dry ice
All compounds are safely and rigorously packed

Payment

Payment terms 30 days net
We are sending the invoice the same day as the shipment
We are able to modify the invoice for the academic institution, so the order can be paid from grants

References

Gandhi, V., Plunkett, W., Weller, S., Du, M., Ayres, M., Rodriguez Jr, C. O., … & Keating, M. J. (2001). Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. Journal of clinical oncology, 19(8), 2142-2152.
Roecker, A. M., Stockert, A., & Kisor, D. F. (2010). Nelarabine in the treatment of refractory T-cell malignancies. Clinical Medicine Insights: Oncology, 4, CMO-S4364.
Kisor, D. F. (2005). Nelarabine: a nucleoside analog with efficacy in T-cell and other leukemias. Annals of Pharmacotherapy, 39(6), 1056-1063.